New combo therapy trial aims to stop nasopharyngeal Cancer's return
NCT ID NCT07238569
Summary
This large Phase 3 trial is testing if adding an oral chemotherapy drug (capecitabine) to a standard immunotherapy drug (adebrelimab) works better to control cancer after initial treatment. It's for patients with advanced nasopharyngeal cancer who still have signs of the Epstein-Barr virus or whose cancer hasn't shrunk enough after initial chemo. The goal is to see if this combination helps keep the cancer from coming back longer and improves survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.